DK2819655T3 - Modafinil til anvendelse til behandling af kokainmisbrugere - Google Patents
Modafinil til anvendelse til behandling af kokainmisbrugere Download PDFInfo
- Publication number
- DK2819655T3 DK2819655T3 DK13715263.3T DK13715263T DK2819655T3 DK 2819655 T3 DK2819655 T3 DK 2819655T3 DK 13715263 T DK13715263 T DK 13715263T DK 2819655 T3 DK2819655 T3 DK 2819655T3
- Authority
- DK
- Denmark
- Prior art keywords
- modafinil
- cocaine
- composition
- treatment
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (7)
1. Farmaceutisk sammensætning på basis af modafinil S til dets anvendelse til substitutionsbehandlingen af kokainmisbrugere, kendetegnet ved, at modafinil S opnås ved det superkritiske fluidums teknologi, idet modafinilen S absorberes på overfladen af granuler, som realiseres i en inert bærer.
2. Sammensætning til anvendelse ifølge krav 1, kendetegnet ved, at det nævnte fluidum er CO2.
3. Sammensætning til anvendelse ifølge krav 1 eller 2, kendetegnet ved, at den nævnte bærer er vandfri lactose.
4. Sammensætning til anvendelse ifølge krav 1 eller 2, kendetegnet ved, at den nævnte bærer er mannitol.
5. Sammensætning til anvendelse ifølge et af kravene 1 til 4, kendetegnet ved, at den nævnte sammensætning præsenterer sig i form af tabletter.
6. Sammensætning til anvendelse ifølge krav 5, kendetegnet ved, at den nævnte tablet indeholder 25 til 200 mg modafinil S.
7. Sammensætning til anvendelse ifølge krav 6, kendetegnet ved, at den nævnte tablet indeholder 50 til 100 mg modafinil S.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1200581A FR2987267B1 (fr) | 2012-02-28 | 2012-02-28 | Application du modafinil dans le traitement de substitution des cacainomanes |
PCT/FR2013/000052 WO2013128088A1 (fr) | 2012-02-28 | 2013-02-25 | Application du modafinil dans le traitement des cocaïnomanes |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2819655T3 true DK2819655T3 (da) | 2016-11-28 |
Family
ID=48083447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13715263.3T DK2819655T3 (da) | 2012-02-28 | 2013-02-25 | Modafinil til anvendelse til behandling af kokainmisbrugere |
Country Status (33)
Country | Link |
---|---|
US (1) | US20150073055A1 (da) |
EP (1) | EP2819655B1 (da) |
JP (1) | JP6163169B2 (da) |
KR (1) | KR101897855B1 (da) |
CN (1) | CN104159575B (da) |
AR (1) | AR090169A1 (da) |
AU (1) | AU2013224831B2 (da) |
BR (1) | BR112014020626A2 (da) |
CA (1) | CA2863159C (da) |
CL (1) | CL2014002203A1 (da) |
CY (1) | CY1118166T1 (da) |
DK (1) | DK2819655T3 (da) |
EA (1) | EA025692B1 (da) |
ES (1) | ES2593276T3 (da) |
FR (1) | FR2987267B1 (da) |
HR (1) | HRP20161165T1 (da) |
HU (1) | HUE030737T2 (da) |
IL (1) | IL234009B (da) |
IN (1) | IN2014DN07831A (da) |
LT (1) | LT2819655T (da) |
MX (1) | MX348222B (da) |
NZ (1) | NZ628009A (da) |
PH (1) | PH12014501837A1 (da) |
PL (1) | PL2819655T3 (da) |
PT (1) | PT2819655T (da) |
RS (1) | RS55238B1 (da) |
SG (1) | SG11201405316WA (da) |
SI (1) | SI2819655T1 (da) |
SM (1) | SMT201600363B (da) |
TW (1) | TWI626042B (da) |
UA (1) | UA113301C2 (da) |
WO (1) | WO2013128088A1 (da) |
ZA (1) | ZA201405910B (da) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105055404B (zh) * | 2015-08-19 | 2017-07-18 | 四川大学 | Hmgcs2抑制剂在制备治疗可卡因成瘾的药物中的用途 |
CN105055412B (zh) * | 2015-08-20 | 2018-06-19 | 四川大学 | Nampt抑制剂在制备治疗可卡因成瘾的药物中的用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618845A (en) * | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
FR2771004B1 (fr) | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
US20010034373A1 (en) | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
JP4593074B2 (ja) * | 2000-10-11 | 2010-12-08 | セフアロン・インコーポレーテツド | モダフィニル化合物含有組成物 |
US20040006532A1 (en) | 2001-03-20 | 2004-01-08 | David Lawrence | Network access risk management |
US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
US7093476B2 (en) | 2004-09-15 | 2006-08-22 | Ut-Battelle, Llc | Method for fabricating thin californium-containing radioactive source wires |
EP1909573A4 (en) * | 2005-07-21 | 2010-09-22 | Neurohealing Pharmaceuticals I | SHORT-TERM EFFECTIVE MODAFINIL COMPOSITIONS WITH A RAPID INITIAL EFFECT, AND METHOD FOR THEIR USE |
CA2657409A1 (en) * | 2006-07-12 | 2008-01-17 | Elan Corporation, Plc | Nanoparticulate formulations of modafinil |
EP1980240A1 (en) * | 2007-04-11 | 2008-10-15 | Cephalon France | Lyophilized pharmaceutical compositions and methods of making and using same |
US8173169B2 (en) * | 2007-07-11 | 2012-05-08 | Hikma Pharmaceuticals | Formulation and process for the preparation of modafinil |
-
2012
- 2012-02-28 FR FR1200581A patent/FR2987267B1/fr not_active Expired - Fee Related
-
2013
- 2013-02-25 CA CA2863159A patent/CA2863159C/fr not_active Expired - Fee Related
- 2013-02-25 LT LTEP13715263.3T patent/LT2819655T/lt unknown
- 2013-02-25 AU AU2013224831A patent/AU2013224831B2/en not_active Ceased
- 2013-02-25 UA UAA201409664A patent/UA113301C2/uk unknown
- 2013-02-25 MX MX2014010237A patent/MX348222B/es active IP Right Grant
- 2013-02-25 RS RS20160882A patent/RS55238B1/sr unknown
- 2013-02-25 DK DK13715263.3T patent/DK2819655T3/da active
- 2013-02-25 NZ NZ628009A patent/NZ628009A/en not_active IP Right Cessation
- 2013-02-25 SG SG11201405316WA patent/SG11201405316WA/en unknown
- 2013-02-25 CN CN201380011342.7A patent/CN104159575B/zh not_active Expired - Fee Related
- 2013-02-25 EA EA201400960A patent/EA025692B1/ru not_active IP Right Cessation
- 2013-02-25 US US14/381,896 patent/US20150073055A1/en not_active Abandoned
- 2013-02-25 BR BR112014020626A patent/BR112014020626A2/pt not_active Application Discontinuation
- 2013-02-25 JP JP2014559270A patent/JP6163169B2/ja not_active Expired - Fee Related
- 2013-02-25 IN IN7831DEN2014 patent/IN2014DN07831A/en unknown
- 2013-02-25 KR KR1020147023180A patent/KR101897855B1/ko active IP Right Grant
- 2013-02-25 PL PL13715263T patent/PL2819655T3/pl unknown
- 2013-02-25 SI SI201330319A patent/SI2819655T1/sl unknown
- 2013-02-25 PT PT137152633T patent/PT2819655T/pt unknown
- 2013-02-25 WO PCT/FR2013/000052 patent/WO2013128088A1/fr active Application Filing
- 2013-02-25 EP EP13715263.3A patent/EP2819655B1/fr active Active
- 2013-02-25 HU HUE13715263A patent/HUE030737T2/en unknown
- 2013-02-25 ES ES13715263.3T patent/ES2593276T3/es active Active
- 2013-02-27 AR ARP130100596A patent/AR090169A1/es unknown
- 2013-02-27 TW TW102106817A patent/TWI626042B/zh not_active IP Right Cessation
-
2014
- 2014-08-07 IL IL234009A patent/IL234009B/en active IP Right Grant
- 2014-08-12 ZA ZA2014/05910A patent/ZA201405910B/en unknown
- 2014-08-14 PH PH12014501837A patent/PH12014501837A1/en unknown
- 2014-08-19 CL CL2014002203A patent/CL2014002203A1/es unknown
-
2016
- 2016-09-12 HR HRP20161165TT patent/HRP20161165T1/hr unknown
- 2016-10-12 SM SM201600363T patent/SMT201600363B/it unknown
- 2016-10-26 CY CY20161101079T patent/CY1118166T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107921032B (zh) | 用于治疗神经学疾病或病症的vmat2抑制剂 | |
US9682069B2 (en) | Methods of treating Dravet syndrome | |
BR112013024401B1 (pt) | Composição farmacêutica sólida oral compreendendo um ingrediente ativo estimulante do sistema nervoso central e o uso terapêutico da mesma | |
JP2008542419A (ja) | 神経刺激性ステロイドの医薬組成物及びその使用 | |
JP2017505786A (ja) | 神経障害の処置のためのバクロフェン、アカンプロセート、及び中鎖トリグリセライドの併用 | |
KR20200053570A (ko) | 기면증의 치료에서 가복사돌의 사용 | |
DK2819655T3 (da) | Modafinil til anvendelse til behandling af kokainmisbrugere | |
WO2019018247A1 (en) | USE OF AMBROXOL TO IMPROVE AND / OR EXTEND THE LIFETIME IN GOOD HEALTH, LIFETIME AND / OR MENTAL ACUITY | |
CN1387434A (zh) | Nk1受体拮抗剂及gaba结构类似物的协同组合 | |
CN111818913B (zh) | 含有拉科酰胺的药剂学缓释性组合物 | |
WO2012129232A1 (en) | Compositions for the treatment of psychotic or neurological disorders | |
CN1929830A (zh) | Nmda受体拮抗剂联合抗癫痫药物治疗癫痫症和其他中枢神经系统疾病的组合物和方法 | |
AU2021404187A9 (en) | Oral compositions comprising ketamine combined with subcutaneal or intravenous ketamine for use in the treatment, control or prevention of depressive disorders | |
KR101565505B1 (ko) | 에페리손을 함유하는 새로운 약물 전달 시스템 | |
CA2562078A1 (en) | Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome | |
BR112017027839B1 (pt) | Uso de inibidores de vmat2 para preparação de uma composição farmacêutica para tratar mania em um transtorno de humor em um indivíduo; e/ou tratar transtorno obsessivo-compulsivo (toc) refratário ao tratamento | |
CN1454597A (zh) | 一种治疗抑郁症的口服缓、控释制剂 |